APECED patients feature selective infection susceptibility to CMC with a frequency of ~80-90%, associated with serum autoantibodies against IL-17F (frequency, ~20-85% depending on the cohort), IL-17A (frequency, ~35%), and IL-22 (frequency, ~70-90% depending on the cohort) [211–214]. This evidence concerns the gene IL17A and infection.